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Abstract
Many different deﬁnitions for multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria are
being used in the medical literature to characterize the different patterns of resistance found in healthcare-associated, antimicrobial-
resistant bacteria. A group of international experts came together through a joint initiative by the European Centre for Disease Pre-
vention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC), to create a standardized international ter-
minology with which to describe acquired resistance proﬁles in Staphylococcus aureus, Enterococcus spp., Enterobacteriaceae (other than
Salmonella and Shigella), Pseudomonas aeruginosa and Acinetobacter spp., all bacteria often responsible for healthcare-associated infec-
tions and prone to multidrug resistance. Epidemiologically signiﬁcant antimicrobial categories were constructed for each bacterium.
Lists of antimicrobial categories proposed for antimicrobial susceptibility testing were created using documents and breakpoints from
the Clinical Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and
the United States Food and Drug Administration (FDA). MDR was deﬁned as acquired non-susceptibility to at least one agent in
three or more antimicrobial categories, XDR was deﬁned as non-susceptibility to at least one agent in all but two or fewer antimi-
crobial categories (i.e. bacterial isolates remain susceptible to only one or two categories) and PDR was deﬁned as non-susceptibility
to all agents in all antimicrobial categories. To ensure correct application of these deﬁnitions, bacterial isolates should be tested
against all or nearly all of the antimicrobial agents within the antimicrobial categories and selective reporting and suppression of
results should be avoided.
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Background
Emergence of resistance to multiple antimicrobial agents in
pathogenic bacteria has become a signiﬁcant public health
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threat as there are fewer, or even sometimes no, effective
antimicrobial agents available for infections caused by these
bacteria. Gram-positive and Gram-negative bacteria are both
affected by the emergence and rise of antimicrobial resis-
tance. As this problem continues to grow, harmonized deﬁni-
tions with which to describe and classify bacteria that are
resistant to multiple antimicrobial agents are needed, so that
epidemiological surveillance data can be reliably collected
and compared across healthcare settings and countries. In
the strictest sense, multidrug-resistant organisms (MDROs)
are labelled as such because of their in vitro resistance to
more than one antimicrobial agent. Infections with MDROs
can lead to inadequate or delayed antimicrobial therapy, and
are associated with poorer patient outcomes [1–4]. Of the
MDROs, highly-resistant Gram-negative bacteria (e.g. multi-
drug-resistant carbapenemase-producing Klebsiella pneumoniae
and Acinetobacter spp.) require special mention; these organ-
isms can be resistant to all currently available antimicrobial
agents or remain susceptible only to older, potentially more
toxic agents such as the polymyxins, leaving limited and sub-
optimal options for treatment [5–7]. The problem of increas-
ing antimicrobial resistance is even more threatening when
considering the very limited number of new antimicrobial
agents that are in development [8,9].
No consensus has yet been reached on the deﬁnition
and use of terms such as ‘multidrug-resistant’, ‘extreme
drug resistant’, ‘extensive, extensively or extremely drug
resistant’ (all XDR – in this document XDR refers to
‘extensively drug-resistant’) and ‘pandrug-resistant’ (PDR)
[10–15], which characterize resistance in MDROs. This
variability precludes reliable comparison of surveillance data
for MDROs and consequently prevents the medical com-
munity from having a complete comprehension of the
extent of the problem of antimicrobial resistance. More-
over, accurate information cannot be conveyed to the
public and to policy makers about the rising threat of
MDROs to public health [16–18]. Adopting standardized
international terminology to deﬁne organisms that are
resistant to a signiﬁcant number of therapeutically active
drugs would be an important step to improve the compa-
rability of surveillance data for these organisms and to
better assess their global, regional and local epidemiological
importance and public health impact.
Purpose
This document proposes deﬁnitions for MDR, XDR and PDR
strains of pathogenic bacteria that are frequently found in
healthcare settings (e.g. Staphylococcus aureus, Enterococcus
spp., Enterobacteriaceae, Pseudomonas aeruginosa and Acineto-
bacter spp.). By applying these deﬁnitions, clinical, reference
and public health microbiology laboratories will use a com-
mon terminology for grading various antimicrobial resistance
proﬁles. This will result in consistent reporting of comparable
data that can reliably track trends of antimicrobial resistance
locally, but also internationally. Moreover, the use of standard
terminology will optimize epidemiological surveillance sys-
tems, facilitating the exchange of information between the
medical community, public health authorities and policy mak-
ers in order to promote the prudent use of antimicrobials
and other public health measures [19–21].
It is important to note that these deﬁnitions are meant
for public health use and epidemiological purposes only. They
are not intended to replace clinical judgment, to contribute
to therapeutic decision-making or to offer guidance in infec-
tion control practices. These areas are beyond the scope of
this document and remain the purview of clinical specialists
and local and national health authorities. Similarly, these deﬁ-
nitions do not represent and should not be construed to
represent any agency determination of policy.
Approaches to Creating Deﬁnitions for
MDR, XDR and PDR
In a joint initiative by the European Centre for Disease
Prevention and Control (ECDC) and the Centers for Dis-
ease Control and Prevention (CDC), a ﬁrst meeting of
experts was held in Stockholm in January 2008. The scope
of the initial meeting was to create deﬁnitions for highly-
resistant, multidrug-resistant bacteria associated with health-
care-associated infections. This group was later expanded
to include additional experts in the diagnosis, therapy and
surveillance of antimicrobial-resistant bacteria, all of whom
are co-authors of this article. The expert group decided to
concentrate on applying the deﬁnitions to S. aureus, Entero-
coccus spp., Enterobacteriaceae (other than Salmonella and
Shigella), P. aeruginosa and Acinetobacter spp., because of the
epidemiological signiﬁcance, the emerging antimicrobial
resistance and the importance of these bacteria within the
healthcare system. Mycobacteria and other bacteria most
commonly associated with community-acquired infections
such as Streptococcus pneumoniae, Salmonella spp., Shigella
spp. and Neisseria gonorrhoeae were excluded, as their resis-
tance patterns have been previously discussed in the litera-
ture by separate groups of experts [22–25]. These
deﬁnitions, however, can also be applied to these organ-
isms in the future, if the respective expert groups wish to
do so.
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A bacterial isolate was considered non-susceptible to an
antimicrobial agent when it tested resistant, intermediate or
non-susceptible when using clinical breakpoints as interpre-
tive criteria, and not epidemiological cut-offs, provided by
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST), the Clinical and Laboratory Standards
Institute (CLSI) [26,27] and/or the US Food and Drug
Administration (FDA). Only acquired antimicrobial resistance
was taken into consideration in creating deﬁnitions for MDR,
XDR and PDR; intrinsic resistance was not addressed. Lists
were later created, however, with organisms within speciﬁc
organism groups (e.g. the Enterobacteriaceae and Enterococcus
spp.) that are intrinsically resistant to certain antimicrobial
agents. This was done to ensure that these antimicrobial
agents would not be taken into account when applying the
deﬁnitions for these organisms.
After comments on the draft manuscript were circulated
among the experts, the proposal for deﬁnitions of MDR,
XDR and PDR bacteria was presented to the ECDC Advi-
sory Forum, the ofﬁcial advisory body to the ECDC, in
October and December 2008. Suggestions from the Advisory
Forum were: (i) to post the proposed deﬁnitions on the in-
ternet for broad discussion, comments and further consulta-
tions by medical professional societies and other expert
groups; (ii) to pilot-test the proposed deﬁnitions by analysing
a database that contained an adequate number of antimicro-
bial resistant organisms; (iii) to convene a second ECDC
Joint Expert Meeting for further review; and (iv) to present
the ﬁnal proposed deﬁnitions to the ECDC Advisory Forum.
In May 2009 and March 2010 the second and third ECDC
Joint Expert Meetings were held in Helsinki, Finland, and
Stockholm, Sweden, respectively, to further reﬁne the deﬁni-
tions. Applying the deﬁnitions as a pilot-test on antimicrobial
susceptibility databases was also discussed. Results from the
analyses that were subsequently performed will be available as
supporting information, but are not included in this document.
This draft version was put on the web for public com-
ments from 22 July until 22 August 2010. The ﬁnal proposed
deﬁnitions were presented to the ECDC Advisory Forum on
30 September 2010.
Previous Deﬁnitions Applied to Bacteria
Resistant to Multiple Antimicrobial Agents
MDR
In literal terms, MDR means ‘resistant to more than one
antimicrobial agent’, but no standardized deﬁnitions for MDR
have been agreed upon yet by the medical community. Many
deﬁnitions are being used in order to characterize patterns
of multidrug resistance in Gram-positive and Gram-negative
organisms [10,16,17,28,29]. The absence of speciﬁc deﬁni-
tions for MDR in clinical study protocols gives rise to data
that are difﬁcult to compare.
One of the methods used by various authors and authori-
ties to characterize organisms as MDR is based on in vitro
antimicrobial susceptibility test results, when they test ‘resis-
tant to multiple antimicrobial agents, classes or subclasses of
antimicrobial agents’ [10,16,17,30]. The deﬁnition most fre-
quently used for Gram-positive [16,31–34] and Gram-nega-
tive [10,18,30,35–37] bacteria is ‘resistant to three or more
antimicrobial classes’. An overview of the variability of these
deﬁnitions is provided in a comprehensive review of MDR in
P. aeruginosa and A. baumannii by Falagas et al. [10], where the
authors note that a sizeable number of studies do not pro-
pose any speciﬁc deﬁnitions for MDR, but the majority deﬁne
MDR as ‘resistant to three or more antimicrobial classes’.
Another method used to characterize bacteria as MDR, is
when they are ‘resistant to one key antimicrobial agent’
[17,38]. These bacterial isolates may have public health
importance due to resistance to only one key antimicrobial
agent, but they often demonstrate cross or co-resistance to
multiple classes of antimicrobials, which makes them MDR.
Creating an acronym for a bacterium based on its resistance
to a key antimicrobial agent (e.g. methicillin resistance in
S. aureus, i.e. MRSA) immediately highlights its epidemiologi-
cal signiﬁcance; the advantage of using this approach for sur-
veillance purposes is that it can be easily applied.
XDR
Bacteria that are classiﬁed as XDR are epidemiologically sig-
niﬁcant due not only to their resistance to multiple antimi-
crobial agents, but also to their ominous likelihood of being
resistant to all, or almost all, approved antimicrobial agents.
In the medical literature XDR has been used as an acronym
for several different terms such as ‘extreme drug resistance’,
‘extensive drug resistance’, ‘extremely drug resistant’ and
‘extensively drug resistant’ [12,15,39,40].
Initially, the term XDR was created to describe exten-
sively drug-resistant Mycobacterium tuberculosis (XDR MTB)
and was deﬁned as ‘resistance to the ﬁrst-line agents isonia-
zid and rifampicin, to a ﬂuoroquinolone and to at least one
of the three-second-line parenteral drugs (i.e. amikacin, kana-
mycin or capreomycin)’ [41,42]. Subsequent to this, deﬁni-
tions for strains of non-mycobacterial bacteria that were
XDR were constructed according to the principle underlying
this deﬁnition for XDR MTB (i.e. describing a resistance pro-
ﬁle that compromised most standard antimicrobial regimens).
Two sets of criteria have mainly been used to characterize
bacteria as XDR. The ﬁrst is based on the number of antimi-
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crobials or classes or subclasses to which a bacterium is
resistant, and the second on whether they are ‘resistant to
one or more key antimicrobial agents’ [16,17,38].
PDR
From the Greek preﬁx ‘pan’, meaning ‘all’, pandrug resistant
(PDR) means ‘resistant to all antimicrobial agents’. Deﬁni-
tions in the literature for PDR vary even though this term is
etymologically exact and means that, in order for a particular
species and a bacterial isolate of this species to be character-
ized as PDR, it must be tested and found to be resistant to
all approved and useful agents. Examples of current deﬁni-
tions are: ‘resistant to almost all commercially available anti-
microbials’, ‘resistant to all antimicrobials routinely tested’
TABLE 1. Staphylococcus aureus;
antimicrobial categories and
agents used to deﬁne MDR, XDR
and PDR (worksheet for categoriz-
ing isolates)
Antimicrobial category Antimicrobial agent
Results of antimicrobial
susceptibility testing
(S or NS)
Aminoglycosides Gentamicin
Ansamycins Rifampin/rifampicin
Anti-MRSA cephalosporins Ceftaroline
Anti-staphylococcal
b-lactams (or cephamycins)
Oxacillin (or cefoxitin)a
Fluoroquinolones Ciproﬂoxacin
Moxiﬂoxacin
Folate pathway inhibitors Trimethoprim-
sulphamethoxazole
Fucidanes Fusidic acid
Glycopeptides Vancomycin
Teicoplanin
Telavancin
Glycylcyclines Tigecycline
Lincosamides Clindamycin
Lipopeptides Daptomycin
Macrolides Erythromycin
Oxazolidinones Linezolid
Phenicols Chloramphenicol
Phosphonic acids Fosfomycin
Streptogramins Quinupristin-
dalfopristin
Tetracyclines Tetracycline
Doxycycline
Minocycline
Criteria for deﬁning MDR, XDR and PDR in S. aureus
MDR (one or more of these have to apply): (i) an MRSA is always considered MDR by virtue of being an MRSA, (ii)
non-susceptible to ‡1 agent in ‡3 antimicrobial categories.
XDR: non-susceptible to ‡1 agent in all but £2 categories.
PDR: non-susceptible to all antimicrobial agents listed.
aOxacillin or cefoxitin represents all other b-lactams (and cephamycins) and resistance to either of these predicts
non-susceptibility to all categories of b-lactam antimicrobials listed in this document, with the exception of the anti-
MRSA cephalosporins (i.e. all categories of penicillins, cephalosporins, b-lactamase inhibitors and carbapenems cur-
rently approved up until 25 January 2011).
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_
infection_article.aspx.
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and ‘resistant to all antibiotic classes available for empirical
treatment’ [10,43,44], making the deﬁnition of PDR subject
to inconsistent use and liable to potential misinterpretation
of data.
Considerations in Creating the Deﬁnitions
Initially, the expert group agreed that three issues needed to
be addressed to develop the deﬁnitions: (i) how to create
antimicrobial ‘categories’ that would be epidemiologically
meaningful; (ii) how to select the antimicrobial categories
and antimicrobial agents to be tested for each relevant bac-
terium; and (iii) how to deﬁne resistance within an antimi-
crobial category.
Creating antimicrobial categories
There has been no standard approach for determining the
types, classes or groups of antimicrobial agents that should
be used when deﬁning MDR, XDR and PDR. Frequently,
chemical structures for antimicrobial classes (e.g. cephalospo-
rins) [45–47], antimicrobial subclasses, (e.g. third-generation
cephalosporins) [48] or speciﬁc antimicrobial agents (e.g. ce-
ftazidime) [49,50] have been used to deﬁne these terms. This
approach is not always conclusive and makes it difﬁcult to
compare results between studies. The expert group, there-
fore, constructed ‘antimicrobial categories’ for each of the
organisms or organism groups with the intent of placing anti-
microbial agents into more therapeutically relevant groups.
These new categories are listed in Tables 1–5 together with
the proposed antimicrobial agents relevant for antimicrobial
susceptibility testing for each organism or organism group.
Deﬁning antimicrobial categories and antimicrobial agents
to be tested for each organism or organism group
Panels of lists of antimicrobial agents were developed for each
organism or organism group, as proposed harmonized tem-
plates that could be used by clinical, reference and pub-
lic health microbiology laboratories that perform in vitro
antimicrobial susceptibility testing, and wish to identify MDR,
TABLE 2. Enterococcus spp.; anti-
microbial categories and agents
used to deﬁne MDR, XDR and
PDR (worksheet for categorizing
isolates)
Antimicrobial
category Antimicrobial agent
Results of
antimicrobial
susceptibility
testing (S or NS)
Species with
intrinsic resistance
to antimicrobial
categories (51)a
Aminoglycosides
(except streptomycin)
Gentamicin (high level)
Streptomycin Streptomycin (high level)
Carbapenems Imipenem
Meropenem
Doripenem
Enterococcus faecium
Fluoroquinolones Ciproﬂoxacin
Levoﬂoxacin
Moxiﬂoxacin
Glycopeptides Vancomycin
Teicoplanin
Glycylcyclines Tigecycline
Lipopeptides Daptomycin
Oxazolidinones Linezolid
Penicillins Ampicillin
Streptogramins Quinupristin-dalfopristin Enterococcus faecalis
Tetracycline Doxycycline
Minocycline
Criteria for deﬁning MDR, XDR and PDR in Enterococcus spp.
MDR: non-susceptible to ‡1 agent in ‡3 antimicrobial categories.
XDR: non-susceptible to ‡1 agent in all but £2 categories.
PDR: non-susceptible to all antimicrobial agents listed.
aWhen a species has intrinsic resistance to an antimicrobial category, that category must be removed from the list in
this table prior to applying the criteria for the deﬁnitions and should not be counted when calculating the number of
categories to which the bacterial isolate is non-susceptible.
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_
infection_article.aspx.
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TABLE 3. Enterobacteriaceae; antimicrobial categories and agents used to deﬁne MDR, XDR and PDR (worksheet for categor-
izing isolates)
Antimicrobial category Antimicrobial agent
Results of
antimicrobial
susceptibility
testing (S or NS)
Species with intrinsic resistance to
antimicrobial agents or categories (51)a
Aminoglycosides Gentamicin Providencia rettgeri (P. rettgeri), Providencia stuartii (P. stuartii)
Tobramycin P. rettgeri, P. stuartii
Amikacin
Netilmicin P. rettgeri, P. stuartii
Anti-MRSA cephalosporins Ceftaroline (approved only for
Escherichia coli, Klebsiella
pneumoniae, Klebsiella oxytoca)
Antipseudomonal penicillins
+ b-lactamase inhibitors
Ticarcillin-clavulanic acid Escherichia hermannii (E. hermanii)
Piperacillin-tazobactam E. hermanii
Carbapenems Ertapenem
Imipenem
Meropenem
Doripenem
Non-extended spectrum
cephalosporins; 1st and
2nd generation cephalosporins
Cefazolin Citrobacter freundii (C. freundii), Enterobacter aerogenes
(E. aerogenes), Enterobacter cloacae (E. cloacae), Hafnia alvei
(H. alvei), Morganella morganii (M. morganii), Proteus penneri
(P. penneri), Proteus vulgaris (P. vulgaris), P. rettgeri, P. stuartii,
Serratia marcescens (S. marcescens)
Cefuroxime M. morganii, P. penneri, P. vulgaris, S. marcescens
Extended-spectrum
cephalosporins; 3rd and 4th
generation cephalosporins
Cefotaxime or ceftriaxone
Ceftazidime
Cefepime
Cephamycins Cefoxitin C. freundii, E. aerogenes, E. cloacae, H. alvei
Cefotetan C. freundii, E. aerogenes, E. cloacae, H. alvei
Fluoroquinolones Ciproﬂoxacin
Folate pathway inhibitors Trimethoprim-sulphamethoxazole
Glycylcyclines Tigecycline M. morganii, Proteus mirabilis (P. mirabilis),
P. penneri, P. vulgaris, P. rettgeri, P. stuartii
Monobactams Aztreonam
Penicillins Ampicillin Citrobacter koseri (C. koseri), C. freundii, E. aerogenes, E. cloacae,
E. hermanii, H. alvei, Klebsiellae spp., M. morganii, P. penneri,
P. vulgaris, P. rettgeri, P. stuartii, S. marcescens
Penicillins + b-lactamase inhibitors Amoxicillin-clavulanic acid C. freundii, E. aerogenes, E. cloacae, H. alvei,
M. morganii, P. rettgeri, P. stuartii, S. marcescens
Ampicillin-sulbactam C. freundii, C. koseri, E. aerogenes, E. cloacae,
H. alvei, P. rettgeri, S. marcescens
Phenicols Chloramphenicol
Phosphonic acids Fosfomycin
Polymyxins Colistin M. morganii, P. mirabilis, P. penneri, P. vulgaris,
P. rettgeri, P. stuartii, S. marcescens
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XDR and PDR. These lists were designed to be as compre-
hensive as possible and reﬂect antimicrobial agents and testing
practices currently used in most countries around the world.
These lists were developed in a stepwise fashion. The ﬁrst
step was to include the antimicrobial agents listed for each
organism or organism group in the CLSI table of ‘Suggested
TABLE 3. Continued
Antimicrobial category Antimicrobial agent
Results of
antimicrobial
susceptibility
testing (S or NS)
Species with intrinsic resistance to
antimicrobial agents or categories (51)a
Tetracyclines Tetracycline M. morganii, P. mirabilis, P. penneri, P. vulgaris, P. rettgeri, P. stuartii
Doxycycline M. morganii, P. penneri, P. vulgaris, P. rettgeri, P. stuartii
Minocycline M. morganii, P. penneri, P. vulgaris, P. rettgeri, P. stuartii
Criteria for deﬁning MDR, XDR and PDR in Enterobacteriaceae
MDR: non-susceptible to ‡1 agent in ‡3 antimicrobial categories.
XDR: non-susceptible to ‡1 agent in all but £2 categories.
PDR: non-susceptible to all antimicrobial agents listed.
aWhen a species has intrinsic resistance to an antimicrobial agent or to the whole category, that agent or category must be removed from the list in this table prior to apply-
ing the criteria for the deﬁnitions and should not be counted when calculating the number of agents or categories to which the bacterial isolate is non-susceptible.
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_infection_article.aspx.
TABLE 4. Pseudomonas aeruginosa;
antimicrobial categories and
agents used to deﬁne MDR, XDR
and PDR (worksheet for categoriz-
ing isolates)
Antimicrobial category Antimicrobial agent
Results of antimicrobial
susceptibility testing
(S or NS)
Aminoglycosides Gentamicin
Tobramycin
Amikacin
Netilmicin
Antipseudomonal carbapenems Imipenem
Meropenem
Doripenem
Antipseudomonal cephalosporins Ceftazidime
Cefepime
Antipseudomonal ﬂuoroquinolones Ciproﬂoxacin
Levoﬂoxacin
Antipseudomonal penicillins
+ b-lactamase inhibitors
Ticarcillin-clavulanic acid
Piperacillin-tazobactam
Monobactams Aztreonam
Phosphonic acids Fosfomycin
Polymyxins Colistin
Polymyxin B
Criteria for deﬁning MDR, XDR and PDR in Pseudomonas aeruginosa
MDR: non-susceptible to ‡1 agent in ‡3 antimicrobial categories.
XDR: non-susceptible to ‡1 agent in all but £2 categories.
PDR: non-susceptible to all antimicrobial agents listed.
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_
infection_article.aspx.
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agents with FDA clinical indications that should be considered
for routine testing and reporting by clinical microbiological lab-
oratories’ [26]. An antimicrobial agent was added or removed,
based on recommendations included in EUCAST’s Expert
Rules [51] and also by applying speciﬁc inclusion and exclusion
criteria. The inclusion criteria required that each antimicrobial
agent: (i) was currently approved as an antibacterial agent in
humans by the European Medicines Agency (EMA) or the
FDA; and (ii) had breakpoints for the organism or organism
group established by either EUCAST [51], CLSI [26] or the
FDA. An antimicrobial agent was excluded from an organism/
organism group list if: (i) the organism or the whole organism
group was intrinsically resistant to the agent; (ii) the agent
achieved therapeutic concentrations only in urine (e.g. nitro-
furantoin); or (iii) the organism exhibits widespread acquired
resistance to the agent (e.g. penicillin for S. aureus). A note-
worthy example of an antimicrobial agent that did not meet
the criteria for inclusion is tigecycline, which does not have
species-speciﬁc breakpoints for Acinetobacter spp. and was
therefore, not included in Table 5.
Although this document does not address deﬁnitions for
individual bacterial species that are intrinsically resistant to
TABLE 5. Acinetobacter spp.; anti-
microbial categories and agents
used to deﬁne MDR, XDR and
PDR (worksheet for categorizing
isolates)
Antimicrobial category Antimicrobial agent
Results of antimicrobial
susceptibility testing
(S or NS)
Aminoglycosides Gentamicin
Tobramycin
Amikacin
Netilmicin
Antipseudomonal carbapenems Imipenem
Meropenem
Doripenem
Antipseudomonal ﬂuoroquinolones Ciproﬂoxacin
Levoﬂoxacin
Antipseudomonal penicillins
+ b-lactamase inhibitors
Piperacillin-tazobactam
Ticarcillin-clavulanic acid
Extended-spectrum cephalosporins Cefotaxime
Ceftriaxone
Ceftazidime
Cefepime
Folate pathway inhibitors Trimethoprim-sulphamethoxazole
Penicillins + b-lactamase inhibitors Ampicillin-sulbactam
Polymyxins Colistin
Polymyxin B
Tetracyclines Tetracycline
Doxycycline
Minocycline
Criteria for deﬁning MDR, XDR and PDR in Acinetobacter spp.
MDR: non-susceptible to ‡1 agent in ‡3 antimicrobial categories.
XDR: non-susceptible to ‡1 agent in all but £2 categories.
PDR: non-susceptible to all antimicrobial agents listed.
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_
infection_article.aspx.
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antimicrobial agents or categories, there are bacterial species
within certain organism groups (i.e. the Enterococcus spp. and
the Enterobacteriaceae) that are intrinsically resistant to one
or more antimicrobial agents within a category or to all
agents within a category. When applying the deﬁnitions for
MDR, XDR and PDR to these organisms, those agents or
categories will need to be removed and not included in the
analysis. Therefore, a separate column was included in
Tables 2 and 3 listing those organisms that have intrinsic
resistance to the antimicrobial agent or category listed in
that row [51].
Finally, available rules of partial or complete cross-resis-
tance from EUCAST [51] and CLSI [26] were applied to
the lists of antimicrobial agents in order to minimize the
number of agents proposed for testing. An example of a
rule for full cross-resistance is when an E. coli isolate is
tested and found to be non-susceptible to ciproﬂoxacin, it
is considered non-susceptible to all ﬂuoroquinolones
[51,52]. Similarly, a S. aureus isolate is considered non-sus-
ceptible to all lincosamides when it tests non-susceptible to
clindamycin [51,53]. When rules of full cross-resistance
could be applied to an antimicrobial category in Tables 1–5,
one agent only from that category was proposed for antimi-
crobial susceptibility testing.
Deﬁning antimicrobial resistance within an antimicrobial
category
In the deﬁnitions proposed for MDR and XDR in this
document, a bacterial isolate is considered resistant to an
antimicrobial category when it is ‘non-susceptible to at least
one agent in a category’. Thus, resistance of a bacterial iso-
late to only one agent within a category is proposed as
a crude indicator of antimicrobial resistance to the entire
category.
In support of this approach used by the National Health-
care Safety Network (NHSN) a bacterial isolate is consid-
ered resistant to a ‘class’ when it is resistant to one or
more antimicrobial agents within that ‘class’ [17,30]. Thus,
according to this deﬁnition, carbapenem resistance in Klebsiel-
la spp. would be deﬁned as ‘resistance to imipenem or me-
ropenem or ertapenem or doripenem’.
Proposed Deﬁnitions for MDR, XDR and
PDR
The deﬁnitions proposed for the characterization of bacterial
isolates that are MDR, XDR or PDR are given in Table 6.
For all three deﬁnitions, non-susceptibility refers to either a
resistant, intermediate or non-susceptible result obtained
from in vitro antimicrobial susceptibility testing.
TABLE 6. Deﬁnitions for multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria
Bacterium MDR XDR PDR
Staphylococcus aureus The isolate is non-susceptible to at least 1 agent
in ‡3 antimicrobial categories listed in Table 1a
The isolate is non-susceptible to at least 1 agent in all
but 2 or fewer antimicrobial categories in Table 1.
Non-susceptibility
to all agents in all
antimicrobial categories
for each bacterium in
Tables 1–5
Enterococcus spp. The isolate is non-susceptible to at least 1 agent
in ‡3 antimicrobial categories listed in Table 2
The isolate is non-susceptible to at least 1 agent in all
but 2 or fewer antimicrobial categories in Table 2.
Enterobacteriaceae The isolate is non-susceptible to at least 1 agent
in ‡3 antimicrobial categories listed in Table 3
The isolate is non-susceptible to at least 1 agent in all
but 2 or fewer antimicrobial categories in Table 3.
Pseudomonas aeruginosa The isolate is non-susceptible to at least 1 agent
in ‡3 antimicrobial categories listed in Table 4
The isolate is non-susceptible to at least 1 agent in all
but 2 or fewer antimicrobial categories in Table 4.
Acinetobacter spp. The isolate is non-susceptible to at least 1 agent
in ‡3 antimicrobial categories listed in Table 5
The isolate is non-susceptible to at least 1 agent in all
but 2 or fewer antimicrobial categories in Table 5.
aAll MRSA isolates are deﬁned as MDR because resistance to oxacillin or cefoxitin predicts non-susceptibility to all categories of b-lactam antimicrobials listed in this docu-
ment, with the exception of the anti-MRSA cephalosporins (i.e. all categories of penicillins, cephalosporins, b-lactamase inhibitors and carbapenems currently approved up
until 25 January 2011).
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_infection_article.aspx.
FIG. 1. Diagram showing the relationship of MDR, XDR and PDR
to each other.
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MDR is deﬁned as non-susceptibility to at least one agent
in three or more antimicrobial categories. XDR is deﬁned as
non-susceptibility to at least one agent in all but two or
fewer antimicrobial categories (i.e. bacterial isolates remain
susceptible to only one or two categories). PDR is deﬁned
as non-susceptibility to all agents in all antimicrobial catego-
ries (i.e. no agents tested as susceptible for that organism).
Thus, a bacterial isolate that is characterized as XDR will
also be characterized as MDR. Similarly, a bacterial isolate
would have to be XDR in order for it to be further deﬁned
as PDR. Fig. 1 illustrates that XDR is a subset of MDR, and
PDR is a subset of XDR. Bacteria that are PDR carry the
most absolute type of antimicrobial resistance possible,
implying that there are no approved antimicrobial agents that
have activity against these strains. One example is presented
in Table 7 for P. aeruginosa. Fig. 2 shows additional examples
of possible antimicrobial susceptibility patterns that can fall
under the deﬁnitions for MDR, XDR and PDR.
Within the deﬁnition for MDR, a unique rule was applied
when deﬁning antimicrobial resistance for a S. aureus isolate
that is an MRSA. Finding an isolate resistant to oxacillin or
cefoxitin predicts non-susceptibility to all categories of b-lac-
tam antimicrobials listed in this document, with the excep-
tion of the anti-MRSA cephalosporins (i.e. all categories of
penicillins, cephalosporins, b-lactamase inhibitors and carba-
penems, currently approved up until 25 January 2011). An
MRSA isolate thus will always be characterized as MDR
because it meets the deﬁnition for MDR, ‘non-susceptible
to at least one antimicrobial agent in three or more catego-
ries’. A very broad spectrum of resistance is also implied
when a bacterial isolate is characterized as XDR, because
the proposed deﬁnition of XDR indicates that such strains
TABLE 7. Pseudomonas aeruginosa; examples of antimicrobial susceptibility proﬁles that ﬁt MDR, XDR and PDR deﬁnitions;
isolate no. 1 is PDR; isolate no. 2 is XDR and isolate no. 3 is MDR
Antimicrobial category Antimicrobial agent
Isolate no. 1
(PDR)
Isolate no. 2
(XDR)
Isolate no. 3
(MDR)
Aminoglycosides Gentamicin Xa X
Tobramycin X b
Amikacin X
Netilmicin X
Antipseudomonal carbapenems Imipenem X X X
Meropenem X X
Doripenem X X
Antipseudomonal cephalosporins Ceftazidime X X
Cefepime X X
Antipseudomonal ﬂuoroquinolones Ciproﬂoxacin X X X
Levoﬂoxacin X
Antipseudomonal penicillins + b-lactamase inhibitors Piperacillin-tazobactam X
Ticarcillin-clavulanic acid X X
Monobactams Aztreonam X X
Phosphonic acids Fosfomycin X
Polymyxins Colistin X
Polymyxin B X
Criteria for deﬁning MDR, XDR and PDR in Pseudomonas aeruginosa
MDR: non-susceptible to ‡1 agent in ‡3 antimicrobial categories.
XDR: non-susceptible to ‡1 agent in all but £2 categories.
PDR: non-susceptible to all antimicrobial agents listed.
aX = non-susceptible to the antimicrobial agent.
bAbsence of an ‘X’ means the antimicrobial agent was either ‘susceptible’ or ‘not tested’.
http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/ARHAI/Pages/public_consultation_clinical_microbiology_infection_article.aspx.
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are susceptible to only one or two categories of antimicro-
bial agents. In contrast to MDR and XDR, however, it is
necessary to test every antimicrobial agent listed for the
respective organism or organism group in Tables 1–5 in
order to conclusively characterize a bacterial isolate as
PDR.
Applicability and Limitations of MDR, PDR
and XDR Deﬁnitions
The proposed deﬁnitions can be applied to results obtained
from antimicrobial susceptibility testing of bacterial isolates
in any clinical, reference or public health microbiology labo-
ratory. However, to apply the deﬁnitions correctly and to
ensure their validity, certain conditions should be present.
It is important to note that overall a bacterial isolate will
be considered non-susceptible to an antimicrobial agent or
antimicrobial category, when it is found to be non-suscepti-
ble by using any of the available interpretative criteria estab-
lished by EUCAST, CLSI or the FDA. Furthermore, for
results to be compared between surveillance systems or
facilities, it will be important to report details about the
methods and interpretive criteria used for antimicrobial sus-
ceptibility testing along with the results from applying the
deﬁnitions for MDR, XDR and PDR.
For these deﬁnitions to be valid and comparable they should
be applied to databases that contain sufﬁciently large numbers
of bacterial isolates that have been tested against all or nearly all
of the antimicrobial agents within the antimicrobial categories
listed in Tables 1–5. Laboratories that utilize selective reporting
protocols must make sure that results from all the antimicrobial
FIG. 2. Examples of 22 possible antimi-
crobial susceptibility patterns that can
fall under the proposed deﬁnitions for
MDR, XDR and PDR. , the isolate is
susceptible to all agents listed in cate-
gory; , the isolate is non-susceptible to
some, but not all agents listed in cate-
gory; , the isolate is non-susceptible to
all agents listed in category; , the iso-
late was not tested for susceptibility to
any agent listed in this category.
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agents tested are available for analysis, including those agents
that might have been suppressed. When too few antimicrobial
agents have been either tested or reported or both, there will
be difﬁculties in applying the deﬁnitions and in particular, in reli-
ably distinguishing XDR from PDR phenotypes [30]. In cases of
incomplete testing, bacterial isolates can only be characterized
as ‘possible XDR’ or ‘possible PDR’ and these results cannot be
compared with other ‘possible XDR’,’possible PDR’ or con-
ﬁrmed XDR and PDR obtained from other studies. This prob-
lem cannot be circumvented by deﬁning precise antimicrobial
resistance proﬁles for the deﬁnitions of ‘possible XDR’ and
‘possible PDR’, because their characterization depends on
which antimicrobial agents are tested and reported.
‘Possible XDR’ and ‘possible PDR’, however, should still
be regarded as markers of extensive resistance and their use
should be encouraged despite limitations in their interpreta-
tion.
When performing routine antimicrobial susceptibility test-
ing on bacterial isolates in clinical microbiology laboratories,
the limited number of agents generally tested will result in
many MDR bacteria being categorized as ‘possible XDR’ or
‘possible PDR’. This practical limitation underscores the
necessity of testing an adequate number of antimicrobial
agents, such as those suggested in Tables 1–5 in this docu-
ment, in order to effectively apply the deﬁnitions. It also
emphasizes the need to test additional agents beyond those
routinely tested in an individual clinical microbiology labora-
tory when a ‘possible XDR’ or ‘possible PDR’ isolate is
encountered. This additional testing might be carried out in
the clinical microbiology laboratory by using a supplemental
panel or by submitting the isolate to a reference laboratory
to allow deﬁnitive classiﬁcation of these bacteria.
When using ‘MDR’ as a measure of epidemiological or
public health signiﬁcance, it will be important to understand
one of the limitations in the construction of the deﬁnition of
MDR proposed in this document, which also exists for those
deﬁnitions currently found in the literature. Bacterial isolates
that are MDR will have many different resistance proﬁles
because by deﬁnition, non-susceptible results for even a sin-
gle agent in only three antimicrobial categories deﬁnes an
organism as MDR. For example, two E. coli isolates, one
resistant to trimethoprim-sulphamethoxazole, cefazolin and
ciproﬂoxacin and the other to ertapenem, gentamicin and
tigecycline, will both be characterized as MDR even though
the agents are different. Further characterizing of resistance
in bacteria that are MDR, based on the agents to which they
are resistant, is beyond the scope of these deﬁnitions.
Moreover, it must be emphasized that although MDR is
an important characterization of multidrug resistance, in this
era of extreme resistance and despite differences in the
interpretation of MDR that can depend on geographical area
and endemicity, countries should place high importance on
monitoring resistant bacteria that are XDR and PDR because
of their public health impact.
Conclusions
Applying these deﬁnitions for MDR, XDR and PDR world-
wide would allow comparability of data and promote better
comprehension of the problem of highly antimicrobial-resis-
tant bacteria. This has not been possible until now, not only
due to the varied deﬁnitions that are being used, but also
because of differences in the antimicrobial agents that are
used for routine antimicrobial susceptibility testing in clinical,
reference and public health microbiology laboratories. The
proposed deﬁnitions for MDR, XDR and PDR present an
opportunity for clinical microbiology laboratories to review
and, if necessary, expand the number of antimicrobial agents
routinely tested against various organisms and organism
groups and to consider testing additional agents when a bac-
terial isolate is encountered that could be XDR and PDR.
The list of antimicrobial agents found in Tables 1–5 can be
used as a guide and it is important to note again that these
lists are based on current information available from the CLSI,
the EUCAST and the FDA together with the opinion of the
Expert Group. These lists will need to be regularly reviewed
and updated as new recommendations are made and as new
antimicrobial agents are approved and become available for
therapeutic use. As the title of the document indicates, these
are interim deﬁnitions that, we hope, will provide some initial
direction for clinicians, medical laboratory technicians and
researchers alike. As the deﬁnitions are applied, we will learn
more about their potential strengths, limitations and applica-
tions in various settings. These lessons learned will not only
advance our understanding of drug-resistant bacteria, but will
also help shape future iterations of these deﬁnitions.
Updates of this document will be posted, when per-
formed, on the website of the European Centre for Disease
Prevention and Control. For access to these updates and to
download tables which can be used as worksheets, please go
to: http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/
ARHAI/Pages/public_consultation_clinical_microbiology_infection_
article.aspx.
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